Jim Tananbaum, M.D., is the founder and chief executive officer of Foresite Capital and Foresite Labs, a U.S.-focused healthcare investment firm with approximately $3.5 billion in assets under management. Tananbaum has been a thought partner for impactful and fast-growing companies, including Alumis, 10x Genomics, Element BioScience and Jazz Pharmaceuticals.

Tananbaum’s career in healthcare investment spans more than three decades. He has founded and led multiple successful companies, including GelTex, Inc., which brought two drugs to market and was acquired, and Theravance Inc. Tananbaum holds an M.D. from Harvard University, an M.B.A. from Harvard while playing rugby, and a B.S. and B.S.E.E. in applied math and electrical engineering/computer science from Yale University.